Roche Holding Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 2/14/2026)
| Balance Sheet | Total Assets | 127,036,849,680.90 | ROE | 33.57 % |
| Balance Sheet | Total Equity | 42,641,228,095.63 | ROA | 12.79 % |
| Cashflow | Capital Expenditures | -4,728,102,565.01 | P/FCF | 24.98 |
| Cashflow | Free Cash Flow | 14,081,999,872.00 | – | – |
| Cashflow | Operating Cash Flow | 22,492,547,687.86 | P/CF | 15.64 |
| Income | Earnings per Share (diluted) | 16.04 | Div. Yield | 2.82 % |
| Income | Net Income | 12,880,000,000.00 | P/E | 27.31 |
| Income | Shares Outstanding | 803,000,000.00 | P/B | 8.25 |
| Income | Total Revenue | 77,602,443,273.49 | P/S | 4.53 |
Ratios calculated on: 10/13/2026
Company Description
Roche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceuticals and Chugai. Its Diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. It develops medicines for the disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its product portfolio consists of Pharmaceuticals, Solutions for Diagnostics and Products for Researchers. Its Pharmaceutical products include ACTEMRA and CellCept. Its Solutions for Diagnostics products include Accu-Chek Active System and Accu-Chek Aviva Nano System. The Company's Products for Researchers include Cedex HiRes and Genome Sequencer FLX System.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.roche.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more